Soledad Aldana Aguinaga

Dr. Soledad Aldana Aguinaga


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2024 in Updates in Surgery
Verified
Journal Article
Closed access
PDF file
MMMartha Patricia Sánchez Muñoz
Martha Patricia Sánchez Muñoz
JBJosé Daniel Reyes Blandón
José Daniel Reyes Blandón
IGIleana Susana Camba Gutierrez
Ileana Susana Camba Gutierrez
CMCarlos Manuel Moreno Mendoza
Carlos Manuel Moreno Mendoza
SASoledad Aldana Aguinaga
Soledad Aldana Aguinaga
COCésar Alberto Ortiz Orozco
César Alberto Ortiz Orozco

17 February 2024 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
MMM. Patricia Sánchez Muñoz
M. Patricia Sánchez Muñoz
ZRZuleyma P. Bello Ramirez
Zuleyma P. Bello Ramirez
EREduardo L. Martínez Rodriguez
Eduardo L. Martínez Rodriguez
JBJosé D. Reyes Blandón
José D. Reyes Blandón
SASoledad Aldana Aguinaga
Soledad Aldana Aguinaga
AYAllison R. Esparza Yáñez
Allison R. Esparza Yáñez

Verified
Journal Article
Open access
PDF file
KPKarina Mireya Palacios
Karina Mireya Palacios
ZHZamira Helena Hernández-Nazará
Zamira Helena Hernández-Nazará
MMMontserrat Maldonado-González
Montserrat Maldonado-González
EMErika Martinez-Lopez
Erika Martinez-Lopez
MMMartha P. Sánchez Muñoz
Martha P. Sánchez Muñoz
BBertha Ruíz-Madrigal
Bertha Ruíz-Madrigal
Metabolically Dysfunctional-Associated Steatotic Liver Disease (MASLD) affects both metabolically healthy obese (MHO) individuals and metabolically unhealthy lean (MUL) individuals. Key genes linked to liver dysfunction, such as MLXIPL, PPARA, and FGF21, are under-researched in humans. We aimed to evaluate the ChREBP–PPARα–FGF21 axis in relation to metabolic liver dysfunction in MHO and MUL individuals. Liver histopathology, biochemical data, anthropometric measurements, mRNA expression as analyzed by qPCR, and heatmap visualization were utilized to identify relationships among variables and discern gene expression patterns. ChREBP–PPARA–FGF21 genes were analyzed in liver, subcutaneous (SAT), and omental adipose tissue (OAT) biopsies from 55 subjects, including metabolically unhealthy obese (MUO), MHO, MUL, and metabolically healthy lean (MHL) subjects as controls. The MHL, MUL, MHO, and MUO groups showed a gradual increase in liver PPARα, with a downward trend in ChREBPβ levels in SAT (p < 0.05). Liver ChREBPβ positively correlated with insulin resistance and FGF21. Levels of OAT ChREBPβ showed a negative correlation with anthropometric measurements and serum insulin levels. These findings suggest coordinated regulation under metabolic stress. Increased FGF21 expression in the MUL and MUO groups may aid as a metabolic biomarker of impaired energy homeostasis and compensatory hepatic response.